Fig. 2

a Follow-up changes of ICS + LABA and OCS after the discontinuation of omalizumab (% change from baseline). Follow-up of changes in medication after the discontinuation of omalizumab for 12 months. There was a 68 % ~77 % reduction in ICS + LABA and a 65 % ~ 72 % reduction in OCS compared with baseline. Follow-up period: time point ± 14 days after omalizumab discontinuation; Time points: 2 months, 6 months, 12 months; Discontinuation of therapy was defined as a gap in therapy of over 56 days. b Dose of ICS + LABA and OCS after omalizumab discontinuation. The dose of ICS + LABA and OCS decreased after the discontinuation of omalizumab. Discontinuation of therapy was defined as a gap in therapy of over 56 days